Informing the drug development and commercialization industry
Cary, N.C. – June 11, 2014 – Industry Standard Research (ISR) today announced the release of their “CRO Quality Benchmarking – Phase I Service Providers” report. This research, based on in-depth surveys collected from 113 pharmaceutical Phase I decision-makers, indicates that SGS Life Sciences out-performs customers’ expectations across a number of critical delivery drivers.
“Loyalty in the clinical research services industry is extraordinarily difficult to achieve,” explained Kevin Olson, CEO of Industry Standard Research. “The challenges associated with professional services industries and other highly regulated industries tend to lead to little differentiation among service providers. While SGS was not the only strong performer, their leadership across many Staff, Operational Excellence, and Financial factors place them in a very strong position,” Olson continued.
The 2014 CRO Quality Benchmarking – Phase I Service Providers report is a comprehensive, Consumer Reports-style assessment of Phase I service providers that captures buyers’ experiences from around the globe. It provides Phase I delivery quality data for the following 27 CROs:
- Biotrial
- CEDRA
- Celerion
- CHDR
- Chiltern
- Clinical Research Services (CRS)
- Covance
- DaVita
- DCRI-Duke
- Frontage
- HungaroTrial
- ICON
- INC Research
- inVentiv Health Clinical
- Medpace
- PAREXEL
- PPD
- PRA
- Premier Research
- Quintiles
- Quotient Clinical
- Rho
- SGS Life Sciences
- Siro Clinpharm
- Theorem
- US Oncology
- WCCT Global
The report provides delivery quality data across the following 27 dimensions:
Staff Characteristics
- Experience of the Phase I unit’s lead investigator
- Minimizing staff turnover
- Project manager quality
- Project team chemistry
- Responsiveness
- Scientific knowledge
- Therapeutic expertise
Operational Excellence
- Data quality
- Local market / Regulatory knowledge
- Meeting database lock timelines
- Meeting first patient / first visit timelines
- Meeting overall project timelines
- Offered innovative solutions
- Patient / volunteer recruitment
- Speed of site start-up
- Technology for real-time access to data
- Timely project communications
- Up-front contingency planning, risk management
Organizational & Finance Characteristics
- Access to “unique” tests, machines, equipment
- Access to a broad range of services beyond clinic / volunteer management
- Access to patient populations
- Financial strength / stability
- Location of Phase I unit(s) in different global regions
- Location of Phase I unit(s) within your country
- Low cost
- Minimizing change orders
- Timely access to open bed / clinic space
Olson continued, “Similar to the rest of our Benchmarking series of reports, this report allows service buyers to make smarter, more informed, confident decisions and provides CROs the ability to understand their competitive strengths and weaknesses to better meet customer needs going forward.”
About Industry Standard Research
Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about our off-the-shelf intelligence and custom research offerings, please visit the company’s Web site at www.ISRreports.com, email info@ISRreports.com, or follow us on Twitter @ISRreports.
